Florian von Raison, MD

Clinical Development Head Neuroscience

France

About

Experience

  • Novartis (14 yrs 6 mos)
    • Clinical Development Head
      Sep 2016 - Present · 9 yrs 10 mos

      Position title Therapeutic Area Head till 9/20. Accountable for clinical strategy and medical excellence for global drug development programs in neuroscience : Multiple Sclerosis, neurodegenerative diseases (Huntington’s disease, SMA) and chronic pain conditions (Migraine prevention) and psychiatry (Depression). Ensure seamless transition from Novartis early development (NIBR) into full development of early compounds in psychiatry and neurology. Neuroscience BD&L activities with evaluation and successful acquisition or in-licensing of early and stage opportunities in neurology and psychiatry. Serve as clinical line function in global matrix organization

    • Global Head of Clinical Development Novartis Ad interim
      Mar 2025 - Nov 2025 · 9 mos

      Leading the clinical development function at Novartis development across all therapeutic areas. More than 1000 associates all over world with major hubs in US, CH, CN, UK, IRL, JP, IN

    • Senior Global Program Head
      May 2013 - Aug 2016 · 3 yrs 4 mos

      Senior Global Program Head for dedicated clinical development program from phase 2a to registration and beyond. Global reach in several neurological as psychiatric diseases. Development programs including orphan diseases and the development of companion diagnostics. Leading cross functional Global Program Teams responsible for bringing innovative and high value CNS therapeutics to the patients and markets. Successful search and evaluation of external clinical development assets in neuroscience. Completion of a complete M&A process in 2015 of a small biotech with an asset in chronic pain. Integration leader of that company within Novartis

  • Merck Serono (Geneva, Geneva, Switzerland)
    • Head of Global Clinical Development Unit
      May 2011 - Dec 2011 · 8 mos

      Head of GCDU Parkinson's disease and new indications. Early and full development strategies (PoC to registration) for neurodegenerative diseases. Head of neurdegenerative diseases biomarker strategy.

    • Senior Medical Director Neurodegenerative Diseases
      Jun 2007 - Apr 2011 · 3 yrs 11 mos

      Full clinical development in neurodegenerative diseases like Parkinson's disease Clinical lead Phase 3 program worldwide in Parkinson's disease and submission prepartion. This program was approved in EU and CH in 2014/2015. NDA in US pending. NDA in 2011 of compound in Major Depressive Disorder together with small biotech partner.

  • Pfizer France (5 yrs 4 mos)
    • Medical Director Clinical Research
      Apr 2006 - May 2007 · 1 yr 2 mos

      Management of a team running clinical operations across the whole Pfizer R+ D pipeline

    • Medical Manager Neurology
      Apr 2004 - Apr 2006 · 2 yrs 1 mo

      Management ot a team of medical affairs physicians and experts in neurology therapeutic area Pfizer (Alzheimer, Migraine, Neuropathic pain, Epilepsy, Parkinson)

    • Medical Advisor Neurology
      Feb 2002 - Apr 2004 · 2 yrs 3 mos

      Medical Affairs Physician in Alzheimer and Epilepsy